DE69533112D1 - Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken - Google Patents

Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken

Info

Publication number
DE69533112D1
DE69533112D1 DE69533112T DE69533112T DE69533112D1 DE 69533112 D1 DE69533112 D1 DE 69533112D1 DE 69533112 T DE69533112 T DE 69533112T DE 69533112 T DE69533112 T DE 69533112T DE 69533112 D1 DE69533112 D1 DE 69533112D1
Authority
DE
Germany
Prior art keywords
silicristin
silidianin
mixtures
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533112T
Other languages
English (en)
Other versions
DE69533112T2 (de
Inventor
Ezio Bombardelli
Paolo Morazzoni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Application granted granted Critical
Publication of DE69533112D1 publication Critical patent/DE69533112D1/de
Publication of DE69533112T2 publication Critical patent/DE69533112T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
DE69533112T 1995-05-23 1995-10-10 Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken Expired - Lifetime DE69533112T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI951047A IT1274549B (it) 1995-05-23 1995-05-23 Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
PCT/EP1995/003993 WO1996037209A1 (en) 1995-05-23 1995-10-10 Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast

Publications (2)

Publication Number Publication Date
DE69533112D1 true DE69533112D1 (de) 2004-07-08
DE69533112T2 DE69533112T2 (de) 2004-10-21

Family

ID=11371650

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69533112T Expired - Lifetime DE69533112T2 (de) 1995-05-23 1995-10-10 Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken

Country Status (21)

Country Link
US (2) US5912265A (de)
EP (1) EP0828500B1 (de)
JP (1) JP3178844B2 (de)
KR (1) KR100290030B1 (de)
CN (1) CN1148181C (de)
AT (1) ATE268183T1 (de)
AU (1) AU709802B2 (de)
CA (1) CA2221753C (de)
DE (1) DE69533112T2 (de)
DK (1) DK0828500T3 (de)
ES (1) ES2222466T3 (de)
FI (1) FI119100B (de)
HK (1) HK1006222A1 (de)
HU (1) HU220627B1 (de)
IT (1) IT1274549B (de)
NO (1) NO317153B1 (de)
PL (1) PL182064B1 (de)
PT (1) PT828500E (de)
RU (1) RU2161488C2 (de)
SI (1) SI0828500T1 (de)
WO (1) WO1996037209A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2432560A1 (fr) 1978-08-02 1980-02-29 Texas Instruments Inc Procede de decapage de metaux, en particulier d'aluminium, au plasma de tetrachlorure de silicium
US6379714B1 (en) 1995-04-14 2002-04-30 Pharmaprint, Inc. Pharmaceutical grade botanical drugs
EP0918746B1 (de) * 1996-08-12 2003-04-09 Celgene Corporation Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
US6239114B1 (en) * 1997-09-26 2001-05-29 Kgk Synergize Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
WO2000066232A2 (fr) 1999-04-30 2000-11-09 Salomon S.A. Chassis articule
FR2792846B1 (fr) 1999-04-30 2001-07-27 Salomon Sa Patin a roues en ligne du type a platine superieure articulee
KR100342942B1 (ko) * 1999-07-05 2002-07-02 민경윤 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물
US20010025027A1 (en) * 2000-03-07 2001-09-27 Sonis Stephen T. Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
WO2002067853A2 (en) * 2000-10-06 2002-09-06 Probiochem, Llc A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine
WO2002083124A1 (en) * 2000-10-06 2002-10-24 Probiochem, Llc A composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
CA2430669C (en) * 2000-11-30 2011-06-14 The Children's Medical Center Corporation Synthesis of 3-amino-thalidomide and its enantiomers
US20040092565A1 (en) * 2001-07-25 2004-05-13 George Kindness Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
EP1314438A1 (de) * 2001-11-23 2003-05-28 Nutricia N.V. Antiproliferative Zusammensetzung
MXPA05003889A (es) * 2002-10-15 2005-06-22 Celgene Corp Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
TWI310312B (en) * 2002-10-31 2009-06-01 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of macular degeneration
EP1569903A4 (de) * 2002-11-06 2009-07-29 Celgene Corp Verfahren zur anwendung von selektivencytokinhemmenden arzneimitteln zur behandlung und betreuung von myeloproliferativenkrankheiten und zusammensetzungen, die diese arzneimittel enthalten
WO2004054501A2 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
EP1581205A1 (de) * 2002-11-18 2005-10-05 Celgene Corporation Verfahren zur verwendung undzusammensetzungen umfassend(+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamid
CN100402023C (zh) * 2003-06-21 2008-07-16 山东绿叶天然药物研究开发有限公司 一种水飞蓟素软胶囊及其制备方法
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
KR100577514B1 (ko) * 2003-10-21 2006-05-10 한미약품 주식회사 비페닐디메틸디카복실레이트, 및 카르두스 마리아누스추출물 또는 이로부터 정제된 실리빈을 함유하는 경구용마이크로에멀젼 조성물
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
NZ548670A (en) * 2004-01-28 2010-05-28 Androscience Corp Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof
US20060084704A1 (en) * 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
JP2007532642A (ja) * 2004-04-14 2007-11-15 セルジーン・コーポレーション 脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
JP2007533760A (ja) * 2004-04-23 2007-11-22 セルジーン・コーポレーション 肺高血圧症を治療し管理するための、ｐｄｅ４モジュレーターの使用方法及びｐｄｅ４モジュレーターを含む組成物
ES2434946T3 (es) 2005-08-31 2013-12-18 Celgene Corporation Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CA2663731C (en) 2006-09-26 2015-05-19 Celgene Corporation 5-substituted quinazolinone derivatives and compositions comprising the same
ES2381215T3 (es) 2006-10-19 2012-05-24 Signal Pharmaceuticals Llc Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos
NZ578914A (en) * 2007-01-08 2012-11-30 Andhoscience Corp Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
US8710272B2 (en) 2007-01-08 2014-04-29 Androscience Corporation Compounds with (1 E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US9000222B2 (en) 2007-01-08 2015-04-07 Androscience Corporation Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
US7907654B2 (en) * 2007-04-27 2011-03-15 Hewlett-Packard Development Company, L.P. Laser diode with a grating layer
EP2175726A4 (de) 2007-07-31 2011-01-05 Androscience Corp Zusammensetzungen mit androgenrezeptorabbauverstärker und verfahren zur prophylaktischen oder therapeutischen behandlung von hautkrankheiten oder haarverlust
UA102078C2 (ru) 2007-09-26 2013-06-10 Селджин Корпорэйшн 6-, 7- или 8-замещенные производные хиназолинона и композиция, которая их содержит, и способ их использования
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
CZ2008407A3 (cs) * 2008-06-26 2009-08-26 Agra Group, A. S. Vodorozpustný prípravek na bázi flavanonol lignanu a zpusob jeho prípravy
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
KR20170007531A (ko) 2008-10-29 2017-01-18 셀진 코포레이션 암의 치료에 사용하기 위한 이소인돌린 화합물
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
EP3351240B1 (de) 2009-05-19 2019-04-10 Celgene Corporation Formulierungen von 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion
KR20120113219A (ko) 2009-12-22 2012-10-12 셀진 코포레이션 (메틸술포닐)에틸 벤젠 이소인돌린 유도체 및 그의 치료 용도
RS56232B1 (sr) 2010-02-11 2017-11-30 Celgene Corp Derivati arilmetoksi izoindolina i kompozicije koje ih obuhvataju i postupci njihove primene
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
JP6132773B2 (ja) 2011-01-10 2017-05-24 セルジーン コーポレイション Ｐｄｅ４及び／又はサイトカインの阻害剤としてのフェネチルスルホンイソインドリン誘導体
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
BR112013023279A2 (pt) 2011-03-11 2016-12-20 Celgene Corp formas sólidas de 3-(-5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona e suas composições farmacêuticas e usos
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
RU2627471C2 (ru) 2011-09-14 2017-08-08 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
BR112014015923B1 (pt) 2011-12-27 2022-02-01 Amgen (Europe) GmbH Comprimidos revestidos de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metano-sulfoniletil]-4 - acetilaminoisoindolina-1,3-diona
ES2885769T3 (es) 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
EP2752201A1 (de) * 2013-01-04 2014-07-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. C-terminale HSP90-Hemmer zur Behandlung von Hypophysenadenomen
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
EP2764866A1 (de) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Hemmer der nedd8-aktivierenden Enzyme
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
TWI546722B (zh) * 2013-12-11 2016-08-21 新益先創科技股份有限公司 控制點感測面板及控制點感測面板設計方法
US20150196562A1 (en) 2014-01-15 2015-07-16 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
US20170172921A1 (en) * 2016-12-14 2017-06-22 Mahmoud Reza Jaafari Polyphenolic compounds encapsualated in long circulating liposomes and use thereof
MX2020013297A (es) * 2018-06-09 2021-05-27 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
CN109432084A (zh) * 2018-12-26 2019-03-08 温州医科大学 一种抗癌组合物及其在药物制备中的应用
CN112494479B (zh) * 2020-12-28 2022-06-21 华中科技大学同济医学院附属同济医院 茶黄素在制备卵巢功能保护药物方面的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2261434A (en) * 1991-11-15 1993-05-19 Inverni Della Beffa Spa New radical scavenging and antipoperoxidant flavanolignans their preparation and formulations for therapeutic use
CN1047944C (zh) * 1993-06-26 2000-01-05 曾庆通 一种治疗慢性肝炎的中药胶囊

Also Published As

Publication number Publication date
ES2222466T3 (es) 2005-02-01
CA2221753A1 (en) 1996-11-28
RU2161488C2 (ru) 2001-01-10
CA2221753C (en) 2001-07-24
WO1996037209A1 (en) 1996-11-28
FI974268A0 (fi) 1997-11-18
JPH10511685A (ja) 1998-11-10
NO975334L (no) 1997-11-20
PT828500E (pt) 2004-08-31
IT1274549B (it) 1997-07-17
DK0828500T3 (da) 2004-08-16
HU220627B1 (hu) 2002-03-28
JP3178844B2 (ja) 2001-06-25
PL323450A1 (en) 1998-03-30
DE69533112T2 (de) 2004-10-21
KR19990014941A (ko) 1999-02-25
PL182064B1 (pl) 2001-10-31
ITMI951047A0 (it) 1995-05-23
EP0828500A1 (de) 1998-03-18
CN1148181C (zh) 2004-05-05
FI974268A (fi) 1997-12-02
ITMI951047A1 (it) 1996-11-23
AU3805195A (en) 1996-12-11
NO317153B1 (no) 2004-08-30
FI119100B (fi) 2008-07-31
EP0828500B1 (de) 2004-06-02
ATE268183T1 (de) 2004-06-15
AU709802B2 (en) 1999-09-09
HUT77966A (hu) 1998-12-28
US6218369B1 (en) 2001-04-17
KR100290030B1 (ko) 2001-05-15
CN1185112A (zh) 1998-06-17
NO975334D0 (no) 1997-11-20
HK1006222A1 (en) 1999-02-19
US5912265A (en) 1999-06-15
SI0828500T1 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DK0490077T3 (da) Antisense-oligonukleotider til behandling af cancer
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
YU56702A (sh) Korišćenje fsh za lečenje neplodnosti
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
PT1007085E (pt) Utilizacao da hormona de crescimento em composicoes para o tratamento da resistencia a insulina no coracao
KR900017599A (ko) 종양 치료용 약학 조성물
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
BR9812466A (pt) Uso de ifn-alfa e amantadina para o tratamento da hepatite c crÈnica
UA36093A (uk) Спосіб лікування хронічного бронхіту
UA31379A (uk) Спосіб лікування ішемічної хвороби серця

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC